Sermorelin purity and testing: what buyers should actually check

Last updated 2026-07-24

what does "purity" even mean for a peptide like sermorelin

When people ask about sermorelin purity, they usually mean two different things at once: is the vial actually sermorelin (identity), and is it free of contaminants, degradation products, and bacterial growth (purity in the strict sense). Both matter, and neither is something you can eyeball. Sermorelin is a synthetic 29-amino-acid fragment of growth hormone-releasing hormone (GHRH), covering the biologically active N-terminal portion of the natural 44-residue hormone. Because it's a peptide, not a small molecule, it degrades differently than a pill sitting in a bottle. Research on GHRP and GHRH-related peptides has specifically looked at enzymatic and serum stability and degradation profiles, because these molecules break down through pathways that are distinct from typical drug degradation and matter a lot for how a compounded product behaves after reconstitution and storage ^[1]. That degradation question is not academic. A peptide that has partially broken down isn't necessarily dangerous, but it may simply not work as intended, and there is no way to tell by looking at clear liquid in a vial whether that's happened.

can you test sermorelin purity yourself at home

No. There is no reliable home test, kit, or simple lab you can mail a vial to for a meaningful purity readout, at least not one built for consumers. The methods researchers actually use to detect and quantify GHRH and its analogs are specialized instruments: triple quadrupole UHPLC-MS/MS, nanoLC-high-resolution mass spectrometry, and capillary electrophoresis with online preconcentration ^[2][3][4]. One 2023 paper describes using cationic exchange solid-phase extraction combined with triple quadrupole UHPLC-MS/MS specifically to detect GHRHs in urine samples at the low concentrations relevant to anti-doping work ^[2]. Another describes an antibody-free, ultrafiltration-based nanoLC-HRMS/MS assay built to catch GHRH peptides in urine at low picogram-per-milliliter levels ^[5]. These are not services a retail buyer can access affordably, and they're built to detect the presence of a compound in a biological sample (blood or urine), not to certify the contents of a vial you bought. There is also a whole research field around immunoaffinity purification methods, comparing different magnetic bead chemistries specifically to pull GHRH peptides out of complex samples before mass spec analysis ^[6]. That level of instrumentation exists because anti-doping labs needed it, not because it's a consumer service. If a seller tells you they've "tested" a peptide for purity, ask exactly what method was used and whether you can see the certificate of analysis. Vague reassurance is not data.

why is sermorelin so hard to detect and verify, technically speaking

Peptides in the 2 to 10 kilodalton range, which includes sermorelin and its analogs, sit in an awkward zone for standard drug testing. They're too large for simple small-molecule chromatography and too small and structurally variable for straightforward antibody-based immunoassays to be fully reliable across all variants. A 2022 paper on probing for peptidic drugs in the 2-10 kDa range in doping control blood samples lays out exactly this challenge, and a related 2024 paper works through chromatographic-mass spectrometric analysis of the same size range in urine ^[7][8]. Anti-doping labs have also built expanded test methods using immunoaffinity purification paired with LC-HRMS/MS specifically to catch peptides above 2 kDa that older methods missed ^[9]. A 2026 paper describes newer nano-LC coupled with quadrupole/orbitrap mass spectrometry approaches for GHRH and its analogs in urine specifically, which tells you the detection science is still actively evolving, not settled ^[10]. This matters for you as a buyer for a simple reason: if world-class anti-doping labs need this much specialized equipment and continuing method development to reliably find and identify GHRH analogs, a $30 test strip or a generic lab panel is not going to tell you what's actually in your vial. Synthetic GHRH analogs, including ones structurally similar to sermorelin, are also a moving target for detection science precisely because chemists keep modifying the molecule (PEGylation, for instance, to extend half-life), which changes how it behaves in any assay built for the parent compound ^[11][12].

what actually goes wrong with unregulated or gray-market peptide vials

The realistic risks with unverified sermorelin are not exotic. They're the boring failure modes of any unregulated injectable: wrong dose, degraded product, contamination, or a vial that isn't what the label says at all. A 2016 investigation, "Operation Resistance," documented falsified antibiotics and biopharmaceutical injectables circulating in Europe, a reminder that counterfeit injectable products are a documented problem in the broader biopharmaceutical supply chain, not a hypothetical one ^[13]. That study wasn't about sermorelin specifically, but it establishes that the underlying problem, fake or substandard injectables entering the market, is real and has been formally investigated. Separately, a 2026 case report describes anterior cervical osteophyte-related dysphagia in a long-term growth hormone user, illustrating that long-term, high-dose growth hormone axis manipulation carries real physical risk over time ^[14]. That case involved growth hormone use broadly, and it's a useful reminder that anything in this hormonal category deserves medical supervision, not that sermorelin specifically causes this. A recent review of peptide and peptide-analog drug use in recreational and professional sport also raises pointed concerns about the safety and legitimacy of self-sourced peptides used outside clinical oversight ^[15]. None of this is about sermorelin being uniquely dangerous. It's about what happens when any injectable peptide is sourced without pharmacy-level quality control.

does sermorelin have FDA approval history, and does that matter for purity

Yes, and this is actually one of sermorelin's advantages over most peptides you'll see marketed online. Sermorelin was previously sold in the US under the brand name Geref, an FDA-approved product. Geref was discontinued as a commercial product; it was not pulled for a safety failure. You can check any drug's FDA approval and marketing history yourself in the Drugs@FDA database ^[16]. That regulatory history matters because most peptides circulating in the gray market (BPC-157, various GHRPs, and others) never had FDA-approved status at all. Sermorelin did. That gives clinicians and pharmacists an actual reference point for dose, formulation, and known effects, rather than starting from zero. Today, sermorelin used clinically comes from compounding pharmacies rather than as a re-launched branded product. Compounding is legal and regulated under federal law: 21 U.S.C. 353a governs pharmacy compounding ^[17], and FDA maintains specific lists of bulk drug substances allowed for compounding under section 503A (21 CFR 216.23) and by outsourcing facilities under 503B (21 CFR 216.24) ^[18][19]. FDA also publishes and updates the bulk drug substances nominated for 503A compounding use ^[20]. This is the legitimate supply chain: a licensed pharmacy sourcing pharmaceutical-grade bulk sermorelin under these rules, compounding it to a prescription, and shipping it with a real chain of custody. That's a meaningfully different purity picture than an unlabeled vial from an offshore "research chemical" seller with no license at all.

sermorelin vs HGH: which one should you actually be asking about purity for

This is the question underneath most purity worries, so let's answer it directly. Sermorelin is not HGH. It's a GHRH analog that stimulates your own pituitary gland to release growth hormone in a pulsatile pattern that mimics natural physiology ^[21]. Injected HGH (somatropin) is the hormone itself, delivered directly, bypassing your pituitary entirely. A 2006 review makes the case that sermorelin may be "a better approach to management of adult-onset growth hormone insufficiency" than direct HGH replacement, precisely because it preserves the feedback loop: your pituitary still controls how much GH gets released, and the therapy stops working (rather than causing over-release) if your pituitary reserve is exhausted ^[21]. That built-in ceiling is a real safety feature, but it's also sermorelin's real limitation. If your pituitary has very limited GH-producing capacity, sermorelin will do much less for you than direct HGH would; the ceiling clinicians talk about only helps you if your gland can still respond to a signal. On purity and quality control specifically, HGH has a much longer track record: it's manufactured as recombinant protein under strict biologic drug manufacturing standards with decades of approved products in the FDA database, checkable directly through Drugs@FDA ^[16]. Sermorelin, in its current market form, exists almost entirely as a compounded product, which means its purity depends entirely on which pharmacy makes it and what bulk substance standard they're sourcing from, not on a single standardized manufacturing process. That's the honest tradeoff: sermorelin gives you a gentler, self-limiting mechanism, but a less standardized supply chain than pharmaceutical-grade recombinant HGH.

what does the actual evidence on sermorelin's effects look like

Worth being precise about what sermorelin research actually shows, separate from purity. A study in hypogonadal men found that growth hormone secretagogue treatment raised serum IGF-1 levels, and a related paper on growth hormone secretagogues discusses their role in managing body composition in hypogonadal males ^[22][23]. These are legitimate, measurable endocrine effects. They are not evidence for anti-aging benefits or athletic performance enhancement, and nobody with a rigorous dataset has shown that. Older pediatric literature (a 1999 review) covers sermorelin's original approved use: diagnosing and treating idiopathic growth hormone deficiency in children ^[24]. There's also more exploratory research: a 2021 paper discusses sermorelin as a potentially effective drug for patients with recurrent glioma, and a 1990 study looked at GH-releasing factor's effect on maternal and fetal pituitary and placental GH secretion during pregnancy ^[25][26]. These are interesting research directions, not established uses, and neither supports off-label enhancement claims. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons looks at therapeutic peptides broadly in orthopaedic applications, including challenges around standardization and evidence quality ^[27], and a companion 2026 Sports Medicine paper on approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance draws a clear line between what has real clinical trial support and what is being used off-label with no such backing ^[28]. If you're researching sermorelin for a specific goal, read what the actual trials measured, not what a seller's landing page implies.

how is sermorelin dosed, and does dosing affect purity risk

Standard sermorelin dosing in adult off-label use typically runs in the range of 200 to 300 mcg per day, injected subcutaneously, usually at bedtime to work with the body's natural nocturnal GH pulse; pediatric growth hormone deficiency dosing (its original approved indication) followed different, weight-based protocols under direct physician supervision ^[24]. These ranges come from clinical use patterns and older FDA labeling for Geref rather than a single modern consensus guideline, so expect some variation between prescribers. Dosing and purity connect in a practical way: a peptide that has degraded from poor storage or a low-quality compounding process may require a higher dose to get any effect, which is exactly the situation where someone might start experimenting with unsupervised dose increases. That's a bad idea. If a prescribed dose doesn't seem to be working, the right move is to go back to the prescriber and question the product or the diagnosis, not to freelance the dose upward. If you want dosing specifics, see our sermorelin overview, and if you're weighing whether reported results match what the studies actually measured, sermorelin peptide before and after walks through that directly.

what should you ask a pharmacy or prescriber about sermorelin sourcing

A short, specific list, worth bringing to an actual conversation rather than trusting a website's About page: Ask whether the pharmacy is a licensed 503A compounding pharmacy or a 503B outsourcing facility, and ask which bulk drug substance list they're sourcing from, since both categories are governed by specific FDA rules (21 CFR 216.23 and 216.24) ^[18][19]. Ask for a certificate of analysis for the specific batch, not a generic one. Ask how the product is shipped and stored (sermorelin needs refrigeration and has a limited stability window after reconstitution). Ask whether a prescriber actually reviewed your case before the product shipped, or whether a prescription was rubber-stamped after a quick online form. A legitimate telehealth or clinic model routes you through an actual prescriber, then fills through a named, licensed pharmacy, with your name on the label and a real batch record behind it. That's a fundamentally different transaction than an unmarked vial from a research-chemical site with no prescriber, no license number, and no way to trace the batch if something goes wrong. If you're comparing where to get a legitimate prescription filled, best place to buy sermorelin and sermorelin reviews cover what that vetting looks like in practice. Sermorelin Co's own model is built around exactly this: a provider reviews your case first, and the prescription is filled through a licensed compounding pharmacy partner, not sold as a bare product.

what are the real safety and long-term considerations, separate from purity

Purity is one axis of risk. The other is what sustained GHRH stimulation does to your body over months or years, which is a separate question from whether any given vial is clean. That's covered in more depth in sermorelin long-term side effects, but the short version: because sermorelin works through your own pituitary rather than delivering GH directly, it has a natural ceiling that direct HGH doesn't have, which is part of why it's generally considered to have a gentler risk profile ^[21]. That ceiling doesn't make it risk-free or turn it into a wellness supplement. It's a prescription therapy for a reason, and reported effects like injection site reactions, flushing, and headache show up in the clinical literature on GHRH-class therapies. If you're considering combining it with another peptide, like tesamorelin, read can stack tesamorelin and sermorelin before assuming that's a straightforward or well-studied combination, because the evidence for stacking is much thinner than the evidence for either peptide alone.

Frequently asked questions

Can I test sermorelin purity myself before injecting it?

No consumer-accessible test reliably confirms sermorelin purity or identity. The methods that actually detect and quantify GHRH peptides, like triple quadrupole UHPLC-MS/MS and nanoLC-HRMS/MS, are specialized anti-doping lab instruments, not something you can access affordably or interpret without training ^[2][5].

Is sermorelin FDA approved right now?

Not currently as a branded product. Sermorelin was FDA-approved and sold as Geref, but that product was discontinued commercially, not withdrawn for a safety failure. Today it's available in the US as a compounded product through 503A or 503B pharmacies under FDA's compounding rules ^[16][18].

What's the difference between sermorelin and HGH?

Sermorelin is a GHRH analog that signals your own pituitary to release growth hormone, preserving your body's natural feedback control. HGH (somatropin) is the hormone itself, injected directly, bypassing the pituitary. Sermorelin's effect depends on how much GH your pituitary can still produce; HGH doesn't have that limitation ^[21].

Why is sermorelin harder to test for than most drugs?

Sermorelin falls in the 2-10 kilodalton peptide range, which is too large for standard small-molecule chromatography and structurally tricky for antibody-based tests. Anti-doping researchers have built specific immunoaffinity and mass spectrometry methods just to reliably detect this size class of peptide ^[6][7][8].

Was Geref (the original sermorelin brand) pulled for safety reasons?

No. Geref was discontinued as a commercial product, which is a business decision, not a safety withdrawal. You can verify a drug's FDA approval and marketing status directly through the Drugs@FDA database ^[16].

What actually goes wrong with unregulated peptide vials?

The documented problems are wrong dose, degraded or inactive product, contamination, and outright counterfeit product. A 2016 investigation, Operation Resistance, documented falsified biopharmaceutical injectables circulating in Europe, confirming this is a real supply chain risk, not a hypothetical one ^[13].

Does a certificate of analysis prove a sermorelin vial is pure?

A legitimate certificate of analysis from a licensed compounding pharmacy is meaningfully better than nothing, since it reflects batch-level testing under FDA-regulated compounding rules ^[18][19]. But you should confirm it's specific to your actual batch, not a generic document reused across lots.

Is compounded sermorelin legal in the US?

Yes, when made by a licensed 503A compounding pharmacy or 503B outsourcing facility using bulk substances on FDA's approved compounding lists, under the authority of 21 U.S.C. 353a and 21 CFR 216.23/216.24 ^[17][18][19]. It requires a valid prescription; it is not legally sold as an over-the-counter research chemical.

How is sermorelin typically dosed?

Adult off-label protocols typically use about 200 to 300 mcg injected subcutaneously once daily, usually at bedtime to align with natural nocturnal GH release. Pediatric growth hormone deficiency dosing followed separate, weight-based protocols under Geref's original labeling and direct physician supervision ^[24].

Can sermorelin be stacked with tesamorelin or other peptides?

Some clinicians discuss combining GHRH-class peptides, but the evidence for stacking sermorelin with tesamorelin specifically is much thinner than the evidence for either used alone. See can stack tesamorelin and sermorelin for a fuller breakdown before assuming it's a safe default.

Does sermorelin purity affect how well it works?

Yes. Peptides degrade through specific enzymatic and stability pathways, and a degraded product may simply underperform rather than cause obvious harm ^[1]. If a prescribed dose isn't producing expected lab changes (like IGF-1 movement), that's a reason to question the product with your prescriber, not to raise the dose yourself.

Why do anti-doping labs care about GHRH detection at all?

Because synthetic GHRH analogs, including ones related to sermorelin, have been used off-label for performance enhancement in sport. Multiple studies describe building specific mass spectrometry and immunoaffinity methods just to catch these peptides in blood and urine samples, reflecting real, documented misuse in athletic settings ^[3][15].

Should I trust a seller who says their peptide is "lab tested"?

Ask exactly what method was used and request the actual certificate of analysis for your specific batch. Vague claims of lab testing without a named method or document are not verification. Reliable identity and purity testing requires equipment like UHPLC-MS/MS, not a generic claim ^[2].

Sources

1. Biomedical Chromatography, 2023 (PMID 37688464): GHRP and GHRH-related peptides have documented enzymatic and serum stability/degradation profiles distinct from typical small-molecule drugs.
2. Analytical Biochemistry, 2023 (PMID 37806509): Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS is used to detect GHRHs in urine samples.
3. Drug Testing and Analysis, 2021 (PMID 34665524): Detection methods for synthetic GHRH analogs continue to advance, reflecting the technical difficulty of identifying these peptides.
4. Electrophoresis, 2023 (PMID 36787346): Capillary electrophoresis with online large volume sample stacking has been developed to separate enantiomeric GHRH analogs.
5. Journal of Pharmaceutical and Biomedical Analysis, 2022 (PMID 35298973): An antibody-free, ultrafiltration-based nanoLC-HRMS/MS assay can detect GHRH peptides in urine at low picogram-per-milliliter concentrations.
6. Journal of Chromatography A, 2020 (PMID 32971474): Different magnetic bead surface chemistries have been compared for immunopurification of GHRH peptides before LC-HRMS analysis.
7. Analytical Science Advances, 2022 (PMID 38716080): Peptidic drugs in the 2-10 kDa range, which includes sermorelin, present specific technical challenges for detection in doping control blood samples.
8. Journal of Mass Spectrometry, 2024 (PMID 38197510): Chromatographic-mass spectrometric methods have been developed specifically for peptidic analytes in the 2-10 kDa range in urine.
9. Drug Testing and Analysis, 2015 (PMID 26382721): An expanded test method using immunoaffinity purification and LC-HRMS/MS was built to catch peptides above 2 kDa that older methods missed.
10. Journal of Pharmaceutical and Biomedical Analysis, 2026 (PMID 41138283): Nano-LC coupled with quadrupole/orbitrap mass spectrometry represents newer, still-developing methodology for detecting GHRH and its analogs in urine.
11. Advanced Drug Delivery Reviews, 2003 (PMID 14499707): PEGylation of GHRH analogues alters the molecule's structure and behavior, complicating detection assays built for the parent compound.
12. The Journal of Sports Medicine and Physical Fitness, 2026 (PMID 41880199): Peptide and peptide-analog drugs, including GHRH-class compounds, are used in recreational and professional sport and bodybuilding outside clinical oversight.
13. Drug Testing and Analysis, 2016 (PMID 26456392): Operation Resistance documented falsified antibiotics and biopharmaceutical injectables circulating in Europe.
14. Frontiers in Surgery, 2026 (PMID 42465868): A case report describes anterior cervical osteophyte-related dysphagia in a long-term growth hormone user.
15. Frontiers in Endocrinology, 2026 (PMID 42395176): Performance-enhancing peptides that modulate the GH-IGF1 axis are increasingly self-administered by patients outside clinical evidence and oversight.
16. FDA, Drugs@FDA database: Sermorelin was FDA-approved and marketed as Geref, a status verifiable through the Drugs@FDA database.
17. 21 U.S.C. 353a, pharmacy compounding: Federal law under 21 U.S.C. 353a governs pharmacy compounding of drug products including sermorelin.
18. 21 CFR 216.23, the 503A Bulks List: FDA maintains a specific list of bulk drug substances permitted for compounding under section 503A.
19. 21 CFR 216.24, the 503B Bulks List: FDA maintains a separate bulk drug substances list governing compounding by 503B outsourcing facilities.
20. FDA, bulk drug substances nominated for compounding: FDA publishes and updates the current list of bulk drug substances nominated for use in 503A compounding.
21. Clinical Interventions in Aging, 2006 (PMID 18046908): Sermorelin stimulates the pituitary to release growth hormone in a manner preserving natural feedback control, distinct from direct HGH replacement.
22. American Journal of Men's Health, 2017 (PMID 28830317): Growth hormone secretagogue treatment in hypogonadal men raised serum IGF-1 levels.
23. Translational Andrology and Urology, 2020 (PMID 32257855): Growth hormone secretagogues have a discussed role in managing body composition in hypogonadal males.
24. BioDrugs, 1999 (PMID 18031173): Sermorelin's original approved use was diagnosing and treating idiopathic growth hormone deficiency in children, with its own dosing protocols.
25. Annals of Translational Medicine, 2021 (PMID 33842627): Sermorelin is discussed as a potentially effective drug for patients with recurrent glioma in exploratory research.
26. The Journal of Clinical Endocrinology and Metabolism, 1990 (PMID 2143200): A 1990 study examined GH-releasing factor's effect on maternal and fetal pituitary and placental GH secretion.
27. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026 (PMID 41490200): A 2026 review covers therapeutic peptides in orthopaedics including challenges around standardization and evidence quality.
28. Sports Medicine (Auckland, N.Z.), 2026 (PMID 41966639): A 2026 review distinguishes approved from unapproved peptide therapies used for musculoskeletal injuries and athletic performance.